Overview
Evotec provides research and development services for drug discovery and development through strategic partnerships with pharma, biotech, and academic groups. Its work relies on proprietary platforms such as iPSC-derived cellular models and machine learning to run experiments and analyze data from early discovery through clinical development, often using patient-derived materials to support precision medicine. Unlike many competitors, Evotec offers an integrated, end-to-end R&D platform within collaborations, combining data-driven biology with cell- and gene-therapy capabilities rather than selling standalone tools. Its goal is to bring new and better medicines to patients faster and at lower cost by making the drug development process more efficient through partnerships.
Work here?Claim your company
Simplify's take
What believers are saying
- Q3 2026 adjusted EBITDA loss narrowed to €1.6 million from €15 million.
- Nine-month discovery and preclinical development revenue rose 24% in 2026.
- Vertex manufacturing and new Plectonic and Odyssey partnerships expand 2027 revenue visibility.
What critics are saying
- Evotec cut 2026 revenue guidance to €570 million–€610 million after milestone delays.
- Project Horizon will eliminate 800 jobs and close four sites through Q1 2027.
- If partnership income keeps slipping, Evotec's asset-light turnaround loses financing and credibility.
What makes Evotec unique
- Vertex chose Evotec's Redmond J.POD for commercial povetacicept manufacturing in September 2026.
- Evotec pairs discovery services with proprietary iPSC, ML, and continuous biologics manufacturing platforms.
- Just – Evotec Biologics keeps Redmond as its center of excellence after Toulouse divestiture.
Help us improve and share your feedback! Did you find this helpful?